Bing

a newly-approved treatment for insomnia characterized by difficulty with sleep maintenance. Shares of Somaxon are up 41.5%. Market News Video produces and distributes online videos about stocks and investing.
Forbes · 8/25/2010
Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company focused ... Somaxon cautions readers that statements included in this press release that are not a description of historical facts are forward-looking statements.For …
PharmiWeb · 7/15/2010
Following are the research actions reported by Reuters on Thursday as of 0713 ET ----- ----- STOCK RESEARCH BY ACTION ... Pharmaceuticals SOMX.O reports theflyonthewall.com ...
Reuters · 11/8/2007
Become a member for free Sign up Sign up
4 Traders · 2/22/2012
Asian stocks were up slightly on Tuesday ... Tranzyme (TZYM) gets taken to Hold from Buy at Canaccord Genuity. Somaxon Pharmaceuticals (SOMX) and Vanda Pharmaceuticals (VNDA) are each downgraded to Hold from Buy at Jefferies. The Health …
Equities · 3/13/2012
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company ... and the impact of any such financing activity on the level of its stock price; the impact of any inability to raise sufficient capital to fund ongoing operations; and ...
Finanzen · 9/20/2010
Investing in biotech and pharmaceutical stocks is often more challenging than other forms of investments. While analyzing retail stock, such as Wal-Mart, for example, requires understanding of the firm's balance sheet and operations, most people are ...
Investopedia · 6/16/2010
Mainly due to GNVC. Based on all our readings, we think it will be the HGSI of 2010. The stock landed a 221mil deal back in January with Novartis. The meeting with the fda will actually be a fda review with no approval decision date. The Drug up for review ...
Examiner · 3/8/2010
In the pipeline Somaxon Pharmaceuticals is waiting on an FDA decision on its experimental anti-insomnia drug Silenor. Somaxon (SOMX) chief financial officer Meg McGilley said it's not addictive, which could give it a competitive edge. A lower-dose generic ...
CNN Money · ByAaron Smith · 3/4/2008
Dec 7 (Reuters) - Somaxon Pharmaceuticals Inc SOMX.O said U.S. health regulators declined to approve its insomnia drug Silenor for the second time this year, knocking as much as two-thirds off the value of its shares. The company had previously …
Reuters · 12/8/2009